[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dietary-assessment\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dietary-assessment":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,78,112],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100610414","early-childhood-dietary-assessment-study-100610414",false,"NCT07227272","Early Childhood Dietary Assessment Study","Enhancing the Accuracy of Self-Reported Dietary Intake in Young Children: Development of Two Proxy Reporting Protocols for Self-Reported Dietary Assessment","ECDAS","Inclusion Criteria:\n\n* Adult caregiver ≥ 18 years old\n* Absence of food allergies or dietary restrictions for medical reasons (for the child)\n* Caregiver reports child likes at least 70% of the study-provided foods from the pre-defined list of food options\n* Caregiver has access to a smartphone device compatible with the EMA platform\n* Caregiver can identify a second adult caregiver with access to a smartphone device compatible with the EMA platform and willing to provide the child with study-provided foods for at least two eating occasions.\n\nExclusion Criteria:\n\n* Caregiver unwilling to feed study-provided foods to their child\n* Caregiver unwilling to take pre-and-post photos of child's eating occasions\n* Caregiver unwilling or unable to identify a second adult caregiver meeting the eligibility criteria\n* Caregiver and child reside in a separate household for \\> 2 days per week\n* Family resides \\>25 miles outside of the Knoxville, Tennessee, metropolitan area.",true,"ALL","2 Years","5 Years",{"count":22,"type":23},40,"ESTIMATED","INTERVENTIONAL",[26],"NA","The goal of this crossover randomized controlled trial is to develop a proxy reporting protocol for a traditional 24-hour dietary recall (24HR) and an ecological momentary assessment (EMA) assisted 24-HR for use among children between the ages of 2 and 5 years. The main aims are to:\n\n1. Assess the usability and feasibility of each proxy-reporting protocol and dietary assessment methodology.\n2. Describe the dietary misreporting captured using each proxy-reporting protocol, and\n3. Explore the accuracy of energy intake estimation of the 24HR and EMA+24HR methods, compared to objectively measured food intake.\n\nDuring the research study, participants will:\n\n1. Be provided with one meal and two snacks each day to provide to their child on three consecutive days. Foods can be offered to their child at times of their choosing, and leftovers will be placed back into reusable food storage containers to be picked up by research study staff. Uneaten foods will be weighed for an objective measure of intake.\n2. The day after study-provided foods are given to the child, the adult caregiver will complete a proxy-reported 24HR phone call with a trained research assistant.\n3. In the EMA+24HR condition, caregivers will be provided access to an online platform where they will upload pre- and post-photographs of all of their child's eating occasions across the three days that study-provided foods are eaten.",[29],"Dietary Assessment",[29,31,32,33],"Assessment","Nutrition","Children","RECRUITING","2026-06-05",{"date":37,"type":38},"2026-06-08","ACTUAL",{"date":40,"type":38},"2025-07-15",{"date":42,"type":23},"2026-12",{"name":44,"class":45},"The University of Tennessee, Knoxville","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":17,"sex":18,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":24,"phases":58,"briefSummary":59,"conditions":60,"keywords":64,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":46},"100569180","investigating-the-effects-of-beef-consumption-on-cognitive-and-brain-health-100569180","NCT06690892","Investigating the Effects of Beef Consumption on Cognitive and Brain Health","Understanding the Cognitive and Brain Health Effects of Increasing Beef Consumption in Young Adults","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and lifestyle considerations and availability for the duration of the study\n* Males and females; Age 19-24\n* Willingness to adhere to the ready-to-eat beef intervention regimen\n* Lives within 75 miles of Lincoln, NE\n* BMI between 18.5 and 39.9\n* Not pregnant or nursing\n* No history of cognitive or metabolic diseases indicated by diagnosis, including neurodegenerative disease, stroke, Type 1 and 2 diabetes, metabolic syndrome, cardiovascular disease, liver disease, kidney disease, and cancer\n* No history of eating or anxiety disorders\n* Willing to discontinue dietary supplement use throughout the duration of the study, if they are consuming supplement at the time of the registration\n* No known contraindication to MRI scans as determined by the MRI screening survey questions\n\nExclusion Criteria:\n\n* Current use of medications that may affect their responses to dietary intervention, such as amphetamines, antidepressants, anti-diabetic medications, laxatives, antibiotics, statins and diuretics.\n* Known intolerance or allergy to beef\n* Current use of nicotine products, including vaping\n* Previous use of nicotine products, including vaping, within the recent 6 months at the time of pre-screening","19 Years","24 Years",{"count":57,"type":23},240,[26],"The goal of this clinical trial is to learn if eating more beef will lead to better cognition and a healthier brain in younger adults. The main questions it aims to answer are:\n\n* Does eating more beef lead to higher scores on cognitive tests and better quality of life?\n* Does eating more beef lead to better brain function?\n\nResearchers will compare participants in the experimental group (participants who will eat 25 ounces of beef every week during the dietary intervention) to control participants (participants who will eat 5 ounces of beef every week during the dietary intervention).\n\nParticipants will:\n\n* Be instructed to prepare and consume ready-to-eat beef meals along with their regular diet and not eat any more beef other than what they are given\n* Visit the study facilities once every week to pick up ready-to-eat beef meals; and complete a brief survey every week to track their consumption of the provided beef meals, and a dietary survey every 4 weeks\n* Visit the study facilities before and after the 12-week of intervention period for researchers to study them",[61,62,29,63],"Dietary Intervention","Dietary Proteins","Cognitive Ability, General",[65,66,67,68],"beef consumption","beef dietary intervention","brain health","cognitive health","2026-05-28",{"date":71,"type":38},"2026-05-29",{"date":73,"type":38},"2025-09-22",{"date":75,"type":23},"2026-09",{"name":77,"class":45},"University of Nebraska Lincoln",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":18,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":24,"phases":89,"briefSummary":91,"conditions":92,"keywords":97,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":46},"100635571","phase-4-combatting-muscle-loss-in-obese-adult-patients-on-glp-1-medications-through-dietary-counseling-and-exercise-during-treatment-evaluates-whether-a-12-week-exercise-and-individualized-nutrition-program-can-reduce-muscle-and-bone-loss-and-improve-strength-fitness-and-function-in-obese-adults-on-glp-1-100635571","NCT07554417","Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment Evaluates Whether a 12-week Exercise and Individualized Nutrition Program Can Reduce Muscle and Bone Loss and Improve Strength, Fitness, and Function in Obese Adults on GLP-1","Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment","Inclusion Criteria:\n\n* Age between 40 and 55 years\n* Body Mass Index (BMI) greater than 30\n* Body fat percentage greater than 30% for males and 40% for females\n* Android to gynoid fat ratio greater than 1.0\n* Currently eligible for GLP-1 therapy\n* No diagnosis of Type II diabetes\n\nExclusion Criteria:\n\n* Presence of abnormal ECG findings, including arrhythmias or ischemic changes\n* Hypertensive response to exercise, defined as systolic blood pressure exceeding 250 mmHg or diastolic pressure exceeding 115 mmHg\n* Hypotensive response to exercise, defined as a drop in systolic pressure greater than 10 mmHg with increasing workload\n* VO₂ max below 15 ml\u002Fkg\u002Fmin\n* Borg Rating of Perceived Exertion (RPE) greater than 19 during submaximal workloads\n* Any contraindications to exercise as defined by ACSM guidelines\n* Musculoskeletal limitations that prevent safe participation in exercise","40 Years","55 Years",{"count":88,"type":23},20,[90],"PHASE4","Obesity remains a critical public health challenge and is associated with increased rates of morbidity, mortality, and chronic disease worldwide. In recent years, glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide, have emerged as highly effective pharmacological treatments for obesity, producing substantial weight loss and favorable metabolic improvements. These medications are now widely prescribed, with estimates suggesting that nearly 12% of Americans are currently using or have previously used GLP-1 therapies. Despite their demonstrated benefits, growing evidence indicates that GLP-1-associated weight loss may be accompanied by unintended reductions in skeletal muscle and bone mass. This potential side effect is of increasing concern, as muscle and bone are essential for metabolic health, physical function, injury prevention, and recovery from illness or surgical intervention.\n\nLoss of skeletal muscle during weight reduction may negatively impact strength, mobility, insulin sensitivity, and long-term health outcomes. These risks may be further compounded in individuals experiencing reduced physical activity, mechanical unloading, or prolonged caloric deficits. In clinical and surgical populations, such as individuals undergoing orthopedic procedures, mechanical unloading and disuse already predispose patients to muscle and bone atrophy. When combined with pharmacologically induced weight loss, these factors may further hinder recovery, impair functional capacity, and compromise musculoskeletal integrity. As GLP-1 therapies are increasingly adopted across diverse populations, understanding how to preserve lean mass and bone health during treatment has become an important clinical and public health priority.\n\nExercise training, particularly resistance training, combined with appropriate nutritional support, has consistently been shown to preserve and enhance skeletal muscle and bone mass during weight loss. Structured exercise interventions can mitigate sarcopenia and osteopenia while improving muscular strength, cardiorespiratory fitness, metabolic health, and overall physical function. Similarly, individualized dietary counseling, particularly when focused on adequate protein intake and nutrient timing, plays a critical role in supporting muscle protein synthesis and skeletal health during caloric restriction. Together, these lifestyle strategies may not only counteract the potential adverse musculoskeletal effects associated with GLP-1 therapy but also enhance treatment efficacy by improving cardiovascular risk profiles, insulin sensitivity, systemic inflammation, and physical resilience.\n\nDespite the growing use of GLP-1 medications, there remains a limited body of prospective research examining structured lifestyle interventions specifically designed to preserve muscle and bone mass during GLP-1-induced weight loss. Addressing this gap is essential to ensure that pharmacological obesity treatments support long-term health, functional independence, and quality of life. Integrating exercise and nutrition interventions into GLP-1 treatment protocols may represent a scalable and clinically meaningful strategy to optimize outcomes and reduce unintended consequences of rapid weight loss.\n\nThe purpose of this study is to evaluate whether a structured lifestyle intervention combining exercise and individualized nutritional counseling can mitigate skeletal muscle mass loss in obese adults undergoing treatment with GLP-1 receptor agonists. The primary objective of this study is to determine whether participation in a structured 12-week exercise program, in conjunction with individualized dietary counseling, preserves skeletal muscle mass and bone mineral density during GLP-1 therapy. Secondary objectives include assessing changes in muscular strength, cardiorespiratory fitness, and overall functional capacity. Findings from this study aim to inform best practices for integrating lifestyle interventions with pharmacological obesity treatments and to support safer, more effective, and functionally protective approaches to weight management in adults receiving GLP-1 therapy.",[93,94,95,96,29],"GLP - 1","Obesity & Overweight","Muscle Loss","Exercise Intervention",[98,99,100,101],"GLP-1","Semaglutide","obesity","exercise intervention","NOT_YET_RECRUITING","2026-04-21",{"date":105,"type":38},"2026-04-28",{"date":107,"type":23},"2026-04-06",{"date":109,"type":23},"2026-08-06",{"name":111,"class":45},"William Marsh Rice University",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":17,"sex":119,"minAge":120,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":123,"phases":4,"briefSummary":124,"conditions":125,"keywords":126,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":46},"100570954","analysis-of-dietary-intake-in-professional-female-football-players-100570954","NCT06713954","Analysis of Dietary Intake in Professional Female Football Players","Analysis of Dietary Intake in Professional Female Football Players: Variations According to Playing Position, Age, and Country","Inclusion Criteria:\n\n* Female or assigned female at birth\n* Playing football professionally\n* At a sub-elite to elite standard\n* Above the age of 18\n* Healthy and free of disease\n\nExclusion Criteria:\n\n* Active supplementation with ergogenic aids\n* Active pregnancy\n* No signing of the consent form","FEMALE","18 Years",{"count":122,"type":23},100,"OBSERVATIONAL","This study evaluates the dietary intake of professional female footballers against nutritional guidelines, analysing differences by age, position, and location (UK vs Spain). Using a cross-sectional design, it will include 20-30 players per club from four clubs, aged 18+, collected via the Snap-N-Send method and analysed with Nutritics software. Variables include energy intake, macronutrients, and micronutrients, with data assessed using MANOVA, t-tests, and Shapiro-Wilk tests. The aim is to determine dietary adequacy and provide insights to improve nutrition education and wellbeing for female athletes.",[29],[127,128,129],"athlete","female","diet","2024-12-03",{"date":132,"type":38},"2024-12-06",{"date":134,"type":38},"2024-12-02",{"date":136,"type":23},"2025-03-01",{"name":138,"class":45},"University Ramon Llull"]